Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GSK1349572 (dolutegravir)
DRUG
2 trials
Sponsors
ViiV Healthcare
, University of North Carolina, Chapel Hill
Conditions
Healthy Adult Females
Infection, Human Immunodeficiency Virus I
Phase 1
GSK1349572 Exposure in Blood, Cervicovaginal Fluid, and Cervical and Vaginal Tissue in Healthy Female Subjects
Completed
NCT01404806
University of North Carolina, Chapel Hill
Healthy Adult Females
Start: 2011-08-31
End: 2012-09-30
Updated: 2013-07-04
Phase 3
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Completed
NCT01227824
ViiV Healthcare
Infection, Human Immunodeficiency Virus I
Start: 2010-10-19
End: 2016-12-27
Updated: 2018-10-09
Related Papers
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
2013-01-08
418 citations